These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27387766)

  • 1. Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.
    Mhaskar R; Djulbegovic B
    JAMA Oncol; 2016 Nov; 2(11):1499-1500. PubMed ID: 27387766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
    Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
    Henry DH; Dahl NV; Auerbach MA
    Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.
    Shord SS; Hamilton JM; Cuellar S
    J Oncol Pharm Pract; 2008 Mar; 14(1):5-22. PubMed ID: 18337436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.
    Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):179-87. PubMed ID: 21972052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of oral iron improves chemotherapy-induced anemia in patients receiving erythropoiesis-stimulating agents.
    Tan J; Du S; Zang X; Ding K; Ginzburg Y; Chen H
    Int J Cancer; 2022 Nov; 151(9):1555-1564. PubMed ID: 35639027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
    Szucs TD; Blank PR; Schwenkglenks M; Aapro M
    Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.
    Shord SS; Cuellar S
    J Am Pharm Assoc (2003); 2008; 48(4):487-93. PubMed ID: 18653424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.
    Cortinovis D; Beretta G; Piazza E; Luchena G; Aglione S; Bertolini A; Buzzoni R; Cabiddu M; Carnaghi C; Danova M; Farina G; Ferrari V; Frascaroli M; Reni M; Tansini G;
    Tumori; 2013; 99(1):45-50. PubMed ID: 23548999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing Chemotherapy-Induced Anemia with Erythropoiesis-Stimulating Agents Plus Iron.
    Whitehead L
    Am J Nurs; 2017 May; 117(5):67. PubMed ID: 28448368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
    Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
    Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced anemia: the story of darbepoetin alfa.
    Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
    Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on safety of ESAs in cancer-induced anemia.
    Glaspy J
    J Natl Compr Canc Netw; 2012 May; 10(5):659-66. PubMed ID: 22570294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
    Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE; ;
    J Clin Oncol; 2008 Jan; 26(1):132-49. PubMed ID: 17954713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin in cancer patients.
    Glaspy JA
    Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
    Wauters I; Vansteenkiste J
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.